Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
by Zacks Equity Research
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance
by Zacks Equity Research
The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
by Zacks Equity Research
Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.
Allscripts, Elligo Health Enter in Strategic Partnership
by Zacks Equity Research
Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.
Walgreens' (WBA) Research Website to Add Value in Healthcare
by Zacks Equity Research
Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why Investors Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
by Zacks Equity Research
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Varian (VAR) Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
STERIS (STE) Banks on Organic Growth, Competition Intense
by Zacks Equity Research
STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.
Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump
by Zacks Equity Research
One stock that you may want to consider dropping is Brookdale Senior Living Inc. (BKD), which has witnessed a significant price decline in the past four weeks.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
STAAR Surgical (STAA) Catches Eye: Stock Moves 8.3% Higher
by Zacks Equity Research
STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
by Zacks Equity Research
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
The $200 Club: Will Facebook Beat Alibaba There First?
by Kevin Cook
When you find great fundamental growth stories that institutions must own, you can buy and trade them for a long time in a bull market.
CVS Health Grows on Specialty Pharmacy amid Retail Woes
by Zacks Equity Research
CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.
Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
by Zacks Equity Research
Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.